Society for Immunotherapy of Cancer (SITC) Annual Meeting - X4 Pharmaceuticals

Society for Immunotherapy of Cancer (SITC) Annual Meeting

Society for Immunotherapy of Cancer (SITC) Annual Meeting

November 2017

X4P-001, an Orally Bioavailable CXCR4 Antagonist, Increases T Cell Infiltration in Human Metastatic Melanoma
Efficacy and Mechanism of Action of CXCR4 Inhibition in B16 OVA Melanoma Model

© Copyright 2024 X4 Pharmaceuticals. All Rights Reserved. Terms of Use | Privacy | Compliance and Ethics